7.1 million preventable cancers in 2022, according to a study by the International Agency for Research on Cancer. Australia is now charting a course toward the complete elimination of cervical cancer by 2035, marking humanity’s first total victory against a form of cancer.
This achievement transforms our understanding of prevention. It demonstrates that with coordinated strategies, humanity can eradicate certain chronic diseases rather than simply treat them.
Australia Crosses the Elimination Threshold with High Vaccination Coverage
Australia becomes the first country in the world to document the imminent elimination of cervical cancer. Epidemiological projections confirm that incidence will fall below the threshold of 4 cases per 100,000 women by 2035.
This performance rests on three measurable pillars. Approximately 78-80% of Australian adolescent girls have been vaccinated against HPV since 2013. 70% of women participate in organized cervical screening. 80% of women screened positive access treatment within three months.
Epidemiological data already confirm the impact. Cervical cancer incidence has dropped 38% among women aged 25-29 between 2005 and 2015. Among women vaccinated before age 17, the incidence of precancerous lesions decreased by 86%.
This trajectory contrasts with the global situation. The WHO still reports 660,000 new cases and 350,000 deaths annually from cervical cancer. 85% of these deaths occur in low- and middle-income countries where access to prevention remains limited.
37.8% of Global Cancers Result from Modifiable Factors
The IARC study reveals the scope of preventable cancer. Of 18.7 million new cases diagnosed in 2022, 7.1 million were attributable to modifiable causes. This proportion of 37.8% establishes the theoretical potential for reducing the global cancer burden.
Tobacco dominates preventable causes with 3.9 million cases attributed to it. Infections follow with 1.8 million cases, primarily linked to HPV viruses, hepatitis B and C, and Helicobacter pylori. Obesity generates 792,000 additional annual cases, while alcohol causes 741,000.
These figures draw a clear hierarchy of interventions. Tobacco control could theoretically prevent one cancer in five. Vaccination against oncogenic infections, as illustrated by the Australian model with HPV, offers the second most powerful prevention lever.
Geographic analysis reveals major disparities. Eastern Europe displays the highest rate of preventable cancers with 57.8% of cases attributable to modifiable factors. Sub-Saharan Africa presents the lowest rate at 25.4%, paradoxically reflecting an environment less exposed to industrial risk factors.
The Vaccination Model Extends to Hepatitis and Soon to Lung Cancers
Australia does not limit its cancer elimination strategy to cervical cancer. The country aims to eliminate hepatitis C by 2030 through direct-acting antiviral treatments. 80% of treated patients achieve sustained viral cure, interrupting transmission and preventing associated liver cancers.
This preventive approach is enriched by new tools. Hepatitis B vaccines, deployed massively since the 1980s, are already reducing liver cancer incidence in younger generations. Taiwan, the first country to systematically vaccinate against hepatitis B, observes an 80% drop in liver cancer incidence among those under 30 years old.
Therapeutic vaccination against established cancers is also progressing. Clinical trials of personalized vaccines against melanoma, developed by artificial intelligence that is already revolutionizing early detection, show response rates of 44% in phase II.
Lung cancers, the leading cause of cancer mortality worldwide, are entering this preventive logic. Smoking cessation programs assisted by pharmacotherapy achieve 25% long-term success. Low-dose CT screening reduces mortality by 20% among heavy smokers aged 50 to 80.
Emerging Countries Develop Strategies Adapted to Their Constraints
Cancer elimination is not limited to developed countries. India is launching the world’s largest HPV vaccination program, targeting 50 million adolescent girls by 2025. The unit cost of 2 dollars per dose, negotiated with Serum Institute, makes the intervention accessible despite budgetary constraints.
Rwanda demonstrates that a low-income country can achieve HPV vaccination coverage of 93%. This performance rests on integration into school programs and mobilization of community health workers. The total program cost represents 0.1% of the national health budget.
Asia is simultaneously developing technological innovations to democratize prevention. China is testing self-testing devices for cervical cancer at 5 dollars per unit, compared to 50 dollars for conventional tests. These innovations reduce access barriers in rural areas.
Sub-Saharan Africa is betting on simplified strategies. Malawi is introducing cervical screening by visual inspection after acetic acid application, practicable by nurses trained in two weeks. This accessible approach identifies 77% of precancerous lesions compared to 85% for conventional cytology.
Primary Prevention Transforms the Global Health Economy
Cancer elimination is redefining healthcare investment priorities. The WHO estimates that significant investments in global HPV vaccination will prevent a substantial number of cancers by the end of the century, generating substantial savings in avoided treatments.
This economic logic extends to other risk factors. Tobacco control policies generate a return on investment of 7 dollars for every dollar invested. Alcohol taxes, which reduce consumption by 10% on average, prevent 74,000 cancers annually according to European modeling.
The pharmaceutical industry is adapting its economic models. Instead of developing only expensive treatments, laboratories are investing massively in prevention. Merck generates 3.1 billion dollars in annual revenues with Gardasil, its HPV vaccine, compared to 12 billion for its curative oncology portfolio.
This economic transition accelerates preventive innovation. Private investments in therapeutic cancer vaccines reached 8.2 billion dollars in 2024, compared to 2.1 billion in 2020. This dynamic is part of the broader revolution in non-addictive therapies that are rethinking our relationship with chronic diseases.
The WHO Sets Ambitious Objectives for the Elimination of Several Major Cancers
The World Health Organization is transforming the Australian experience into a global strategy. The WHO is developing initiatives targeting several preventable cancers among the most widespread.
This strategy rests on precise incidence thresholds. Elimination is defined as fewer than 4 cases per 100,000 inhabitants per year for cervical cancer, fewer than 2 per 100,000 for liver cancer linked to viral hepatitis. These objectives, ambitious but achievable according to epidemiological modeling, will guide health investments in the coming decades.
The progressive elimination of these cancers would prevent a significant number of annual deaths by 2050. This perspective transforms the fight against cancer from a defensive battle into an offensive strategy of targeted eradication.
Australia, in being the first to cross this historic barrier, demonstrates that humanity can definitively defeat certain forms of cancer. This scientific victory opens the era of systemic preventive medicine, where elimination progressively replaces treatment as the primary objective of public health.